Protego focuses on the discovery and development of first-in-class small-molecule therapeutics that aim to reprogram protein folding for the treatment of various diseases.
We are exploring monogenetic protein misfolding diseases that cause myopathy, cardiomyopathy, stroke, renal disease, retinal diseases, channelopathies, and various degenerative diseases.
Our approach builds on the proven pharmacological chaperones approach previously exemplified by tafamidis, which was discovered and developed by our cofounders Dr. Jeffery W. Kelly and Dr. Richard Labaudinière, for the treatment of transthyretin amyloidosis.
Company Details
- Employees
- 22
- Address
- 10945 Vista Sorrento Pkwy,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.protegobio.com
- HQ
- San Diego, California
Protego Bio Questions
Protego Bio's website is http://www.protegobio.com
Protego Bio's LinkedIn profile is https://www.linkedin.com/company/protegobio
Protego Bio has
22 employees.
View email and phone details for 22
employees at Protego Bio.
Protego Bio's industry is
Biotechnology Research
Protego Bio's top competitors are
Treeline Biosciences,
Trutino Biosciences,
Cure Rare Disease,
Poseida Therapeutics, Inc.,
Boundless Bio,
Crinetics Pharmaceuticals,
Belharra Therapeutics,
Avidity Biosciences, Inc.,
Travere Therapeutics,
Actio Biosciences, Inc..
Protego Bio's categories are Biotechnology Research
